Bird Law Group, P.C.
Resolute Team of Trial Attorneys — Renowned in Georgia
404-873-4696 888-392-4312
free consultation

Drug manufacturer negligence suspected in Georgia man's death

Residents of Atlanta, just like all American consumers, trust the people responsible for manufacturing pharmaceutical drugs to always keep patient safety in mind. Prescription medications can provide invaluable relief from the suffering of certain conditions.

But occasionally the side effects of medications are so serious that the risks outweigh the benefits. When a drug company fails to disclose safety risks to the Federal Food and Drug Administration, sometimes dangerous drugs receive market approval and medical professionals believe they are safe to prescribe to their patients.

Pradaxa is a drug manufactured by the company Boehringer Ingelheim as a blood-thinner, which is useful for patients at risk for blood clots. It was approved by the FDA as safe for consumer use in 2010, but it was soon suspected as a possible factor in more than 500 deaths.

One of these deaths was of a Georgia man, who reportedly died from excessive gastrointestinal bleeding just one week after being prescribed Pradaxa. His two daughters have filed a product liability lawsuit against Boehringer Ingelheim, claiming the company blatantly ignored consumer safety by failing to warn of the possibility of uncontrollable bleeding.

For the families of patients who die after ingesting dangerous drugs that were thought to be safe, the sense of injustice can be overwhelming. And while nothing can bring back a lost loved one, the relatives of a victim can bring a claim for manufacturer negligence against a pharmaceutical company. A victim's survivors can recover compensation for medical expenses, pain and suffering, loss of earning capacity and loss of companionship. Moreover, they can send a message to drug manufacturers that public safety, not profit, must be their primary goal.

Source: Injury Lawyer News, "Father's Death Leads to Pradaxa Lawsuit Filed By Daughters," Perry Larkin, Dec. 28, 2012

No Comments

Leave a comment
Comment Information
Back To Top